Imunon schedules R&D Day to discuss IMNN-001 ovarian cancer trials

IMUNON, Inc. (Nasdaq: IMNN) announced the agenda and speaker lineup for its R&D Day event, scheduled for September 23, 2026, at 10:00 a.m. ET at the Sofitel New York in New York City. The event will also be available via live webcast.

The event will feature presentations on IMNN-001, the company's investigational IL-12 immunotherapy for advanced ovarian cancer. Speakers will include researchers and principal investigators from the company's ongoing Phase 3 OVATION 3 clinical trial and its Phase 2 minimal residual disease (MRD) study, conducted in partnership with the Break Through Cancer Foundation.

Scheduled presentations include updates on IMNN-001 clinical data, a discussion of the Phase 3 OVATION 3 trial design, and translational findings from the MRD study. A conversation with a participant from the earlier OVATION 1 clinical trial is also planned.

Confirmed speakers include Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON; Douglas V. Faller, M.D., Ph.D., Chief Medical Officer; Amir Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center; Premal H. Thaker, M.D., from Washington University School of Medicine; and William Bradley, M.D., from the Medical College of Wisconsin.

IMNN-001 is a DNA plasmid-based therapy delivered via the company's TheraPlas platform, designed to produce IL-12 protein locally at the tumor site. The therapy has been evaluated in multiple clinical trials, including the completed Phase 2 OVATION 2 study, which enrolled 112 patients with newly diagnosed advanced ovarian cancer.

A live Q&A session and networking opportunities are scheduled to follow the formal presentations. The event is open to investors, media, and stakeholders attending in person or virtually.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Empire Petroleum (EP) files $150M mixed shelf
• Kite Realty Group Trust files for 12M share offering by selling stockholders